RNA Editing

Rewriting the Script: The Past, Present, and Future of RNA Editing Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

Oncology

From Chemo to Advanced Therapies: New Frontiers in Oncology

Serene Lee

Nice Insight

Gene Therapy

Gene Therapy at 30: Milestones, Setbacks, and a Path Forward

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Multispecific Abs

Strategic Biomanufacturing Partner for Multispecific Antibodies

Jina Kim; Busol Park; Youngsun Kim

Samsung Biologics

Cell Therapy

Expanding the Frontiers of Cell Therapy: Veterinary Applications and Translational Insights

April Stanley, MS MBA; Sophie Lutter, Ph.D.

Nice Insight

RNA

Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate

Cynthia A. Challener, Ph.D.; April Stanley, MS MBA

Pharma's Almanac

RNA

What new opportunities are emerging for mRNA technology, and how is the portfolio of applications expanding beyond vaccines?

Pharma's Almanac

OMVs and EVs

Driving Therapeutic Innovation with OMVs and EVs

Ola Tuvesson; Isa Lindgren, Ph.D.

NorthX Biologics

RNA

Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

Aging

Resetting the Biological Clock: OKSM and the Reversal of Aging

David Alvaro, Ph.D.

Pharma's Almanac

LOGIC GATES

Boolean Biology: The Future of Logic-Gated Cell and Gene Therapies

David Alvaro, Ph.D.

Pharma's Almanac

HTS

The High-Throughput Screening Transformation in Modern Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Immuno-oncology

Immuno-Oncology at the Forefront of Cancer Medicine

David Alvaro, Ph.D.

Pharma's Almanac

Small Biotechs

Five Small Biotechs to Watch: March 2025

David Alvaro, Ph.D.

Pharma's Almanac

Radioconjugates

Rising Interest in Radioconjugate Therapies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

xRNA

Revolutionizing xRNA Production: The Economic Case for Continuous Manufacturing

Aaron B. Cowley, Ph.D.

ReciBioPharm